YM BioSciences plans pivotal NSCLC trial for nimotuzumab

 
• By Malini Guha

YM BioSciences' experimental EGFR-targeted humanised monoclonal antibody drug nimotuzumab (YMB1000-015) will not progress to a pivotal trial in colorectal cancer at this time, but the Canadian company instead proposes to advance it into two other pivotal trials this year, including one in non-small cell lung cancer (NSCLC), which it believes could result in faster marketing approval.

YM BioSciences' experimental EGFR-targeted humanised monoclonal antibody drug nimotuzumab (YMB1000-015) will not progress to a pivotal trial in colorectal cancer at this time, but the Canadian company instead proposes to advance it into two other pivotal trials this year, including one in non-small cell lung cancer (NSCLC), which it believes could result in faster marketing approval.

YM's chief executive, David Allan, said the company was "most encouraged" by the results of a single-arm Phase II study...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapeutic Category